Short Interest in Biotricity, Inc. (NASDAQ:BTCY) Expands By 23.7%

Biotricity, Inc. (NASDAQ:BTCY) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 443,400 shares, a growth of 23.7% from the March 31st total of 358,400 shares. Approximately 5.6% of the shares of the stock are sold short. Based on an average daily volume of 96,900 shares, the days-to-cover ratio is presently 4.6 days.

Institutional Trading of Biotricity

An institutional investor recently bought a new position in Biotricity stock. Advisor Resource Council bought a new position in shares of Biotricity, Inc. (NASDAQ:BTCY) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 79,070 shares of the company’s stock, valued at approximately $117,000. Advisor Resource Council owned approximately 0.84% of Biotricity at the end of the most recent quarter. Hedge funds and other institutional investors own 3.89% of the company’s stock.

Biotricity Stock Performance

Shares of Biotricity stock traded up $0.03 on Monday, reaching $1.31. 136,281 shares of the stock were exchanged, compared to its average volume of 85,588. The firm’s 50 day moving average is $1.26 and its 200-day moving average is $1.17. Biotricity has a one year low of $0.70 and a one year high of $4.45.

Biotricity (NASDAQ:BTCY) last released its earnings results on Tuesday, February 20th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.07. The business had revenue of $2.97 million for the quarter, compared to the consensus estimate of $3.00 million. As a group, equities research analysts forecast that Biotricity will post -1.55 earnings per share for the current fiscal year.

About Biotricity

Biotricity, Inc, a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.